- Home
- JMSB vs OTLK Comparison
JMSB vs OTLK Comparison
Compare JMSB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | OTLK |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 249.6M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JMSB | OTLK |
|---|---|---|
| Price | $23.32 | $1.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $23.00 | $2.50 |
| AVG Volume (30 Days) | 30.1K | ★ 13.4M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | 24.17 | ★ 55.91 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $17.09 | $1,430.98 |
| Revenue Next Year | $10.03 | $173.23 |
| P/E Ratio | $54.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.50 | $0.16 |
| 52 Week High | $24.26 | $3.39 |
Technical Indicators
Market Signals| Indicator | JMSB | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 41.12 |
| Support Level | $20.72 | $0.75 |
| Resistance Level | N/A | $1.83 |
| Average True Range (ATR) | 0.77 | 0.18 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 65.15 | 18.48 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.